Previous 10 | Next 10 |
DUBLIN, Ireland, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, today announced upd...
The following slide deck was published by Prothena Corporation plc in conjunction with their 2020 Q2 earnings Read more ...
Prothena (NASDAQ: PRTA ) : Q2 GAAP EPS of -$0.66 misses by $0.05 . More news on: Prothena Corporation plc, Earnings news and commentary, Healthcare stocks news, Read more ...
Net cash used in operating and investing activities was $18.7 million in the second quarter and $41.9 million for the first six months of 2020; quarter-end cash and restricted cash position of $336.6 million provides funding to advance a broad pipeline DUBLIN, Ireland, Aug. 06, 2020 ...
Phase 2 PASADENA Part 1 study results selected as an oral Top Abstract DUBLIN, Ireland, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for...
DUBLIN, Ireland, July 30, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeleine of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, announced today that i...
DUBLIN, Ireland, May 27, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, today announced that members of its senior management team will present and participate in the Jefferies Virtual Healthcare C...
The following slide deck was published by Prothena Corporation plc in conjunction with their 2020 Q1 earnings Read more ...
Prothena (NASDAQ: PRTA ): Q1 GAAP EPS of -$0.59 misses by $0.02 . More news on: Prothena Corporation plc, Earnings news and commentary, Healthcare stocks news, Read more ...
Net cash used in operating and investing activities was $23.2 million in the first quarter; quarter-end cash and restricted cash position of $355.4 million provides funding to advance a broad pipeline DUBLIN, Ireland, May 06, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRT...
News, Short Squeeze, Breakout and More Instantly...
Prothena Corporation plc Company Name:
PRTA Stock Symbol:
NASDAQ Market:
Prothena Corporation plc Website:
2024-07-03 23:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-02 10:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Prothena to receive $80 million from Bristol Myers Squibb for exclusive global license to PRX019, a potential treatment of neurodegenerative diseases with an undisclosed target Prothena will initiate a Phase 1 clinical trial for PRX019 in 2024 Prothena Corporation plc (NASDAQ:PRTA),...